The low-virulent African swine fever virus (ASFV/NH/P68) induces enhanced expression and production of relevant regulatory cytokines (IFNalpha, TNFalpha and IL12p40) on porcine macrophages in comparison to the highly virulent ASFV/L60.
The impact of infection by the low-virulent ASFV/NH/P68 (NHV) and the highly virulent ASFV/L60 (L60) isolates on porcine macrophages was assessed through the quantification of IFNalpha, TNFalpha, IL12p40, TGFbeta and ASFV genes by real-time PCR at 2, 4 and 6 h post-infection. Increased IFNalpha, TNFalpha and IL12p40 expression was found in infection with NHV, in which expression of TGFbeta was lower than in infection with L60. Principal component analysis showed a positive interaction of cytokines involved in cellular immune mechanisms, namely IFNalpha and IL12p40 in the NHV infection. Quantification by ELISA confirmed higher production of IFNalpha, TNFalpha and IL12p40 in the NHV-infected macrophages. Overall, our studies reinforce and clarify the effect of the NHV infection by targeting cellular and cellular-based immune responses relevant for pig survival against ASFV infection.
Gil
S
S
Faculdade de Medicina Veterinária, Laboratório de Doenças Infecciosas, CIISA, Technical University of Lisbon, Lisbon, Portugal.
Sepúlveda
N
N
Albina
E
E
Leitão
A
A
Martins
C
C
D000358:African Swine Fever Virus / Q000276:immunology* / Q000472:pathogenicity*; D000818:Animals; D016207:Cytokines / Q000096:biosynthesis*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D020869:Gene Expression Profiling; D008264:Macrophages / Q000276:immunology*; D016133:Polymerase Chain Reaction / Q000379:methods; D025341:Principal Component Analysis; D014774:Virulence
D016207:Cytokines
Nat Rev Immunol. 2003 Feb;3(2):133-46
12563297
J Virol Methods. 1998 Nov;75(1):113-9
9820580
Arch Virol. 1993;129(1-4):211-25
8470951
Am J Vet Res. 1969 Aug;30(8):1343-59
4894999
J Virol. 1996 Dec;70(12):8527-33
8970976
Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):634-9
9012836
Arch Gesamte Virusforsch. 1967;21(3):349-56
4300741
Vet Immunol Immunopathol. 1996 Nov;54(1-4):45-55
8988847
Am J Vet Res. 1989 Oct;50(10):1781-6
2802312
Arch Virol. 1983;76(2):73-90
6307224
Arch Virol. 2000;145(8):1639-57
11003474
Biochem Pharmacol. 2006 Nov 30;72(11):1469-76
16846591
J Virol. 2004 Feb;78(4):1858-64
14747550
Arch Virol. 2003 Nov;148(11):2077-97
14579171
J Virol Methods. 1982 Jan;3(6):303-10
7085838
Viral Immunol. 1987-1988;1(3):177-90
3509675
Vet Immunol Immunopathol. 1992 May;32(3-4):243-59
1632065
Am J Vet Res. 1960 Jan;21:104-8
14420403
J Exp Med. 1995 Mar 1;181(3):901-14
7869050
Trends Biotechnol. 2004 Aug;22(8):395-9
15283983
Semin Immunol. 1998 Oct;10(5):383-90
9799713
Bull Epizoot Dis Afr. 1968 Sep;16(3):341-3
4180037
J Virol. 2001 Nov;75(21):10372-82
11581405
Am J Vet Res. 1966 Mar;27(117):477-84
4959954
Immunology. 1997 Jul;91(3):444-9
9301535
Vet Rec. 1969 Dec 13;85(24):668-74
5391024
J Gen Virol. 1977 Mar;34(3):455-63
856945
J Gen Virol. 2001 Mar;82(Pt 3):513-523
11172092
J Virol. 1984 Oct;52(1):37-46
6384555
J Virol. 2001 Apr;75(7):3066-76
11238833
Vet Immunol Immunopathol. 2004 Aug;100(3-4):117-34
15207450
Annu Rev Immunol. 2005;23:307-36
15771573
J Gen Virol. 2005 Sep;86(Pt 9):2445-2450
16099902
J Immunol. 1996 Feb 1;156(3):1138-42
8557990